Innovative oncology projects rewarded: Unicancer and the Health Data Hub unveil the 3 winners of the UNIBASE Call for Expression of Interest (AMI)

UNICANCER, MONDAY APRIL 11, 2022

Unicancer and the Health Data Hub (HDH) unveiled yesterday the 3 winners of their first AMI UNIBASE, as part of a joint event organized at PariSanté campus. Sophie Beaupère, General Delegate of Unicancer and Stéphanie Combes, Director of the HDH presented the prizes to the three selected projects which will benefit from the support of these two major players in oncology as well as a financial subsidy from the HDH. At the end of the ceremony, a round table was held on the theme “Cancer and health data”.

A joint AMI under the UNIBASE program

Unicancer and the HDH signed a partnership agreement in July 2021, in order to launch the UNIBASE project, the realization of their common ambition to accelerate research from real life data in the field of cancer. In the process, an AMI was launched in order to select innovative and mature projects, bringing together data from several Centers for the fight against cancer (CLCC) thus allowing the application of artificial intelligence methods.

For this first CEI, the CLCC network was strongly mobilized: 10 projects were proposed involving nearly 50 teams spread over 8 CLCCs sometimes associated with academic or industrial partners.

The selection panel, chaired by Dr Bertrand Lukacs (specialist in the use of data in urology and oncology, SNDS expert) was made up of:

– 2 representatives of Unicancer: Coralie Courtinard, Mathieu Robain
– 2 HDH representatives: Emmanuel Bacry, Roman Hossein Khonsari
– 1 citizen representative: Jean-Marie Vital from the association of parents and friends of children treated for cancer at the Gustave Roussy Institute
– 2 representatives of the HDH Scientific Advisory Board: Bernard Hamelin, Bertrand Lukacs.

The three winners of the AMI UNIBASE

Infertility Secondary to Breast Cancer Treatments, REALIGIST and DASTO UNIBASE were selected by the jury. Benefiting from personalized support and dedicated funding, they can also be carried out on the HDH’s technological platform.

We are delighted with the success of this first AMI, concretization of the mobilization and expertise of the Centers of the Unicancer network. Innovative projects will be able to see the light of day and benefit from the support of Unicancer and the HDH, always for the benefit of patients. says Sophie Beaupère, General Delegate of Unicancer.

The Health Data Hub will bring together data from different centres, cross-check them with other data sources, pool them and enrich them. With this UNIBASE partnership, we will be able to simplify the realization of these impactful multicentric projects. explains Stéphanie Combes, director of the Health Data Hub.

ISIS
As the age of first pregnancy increases, more and more women will be diagnosed with cancer before having their first child. The decline in fertility induced by cancer therapies has an impact on the quality of life of patients who have been treated for breast cancer. Better knowledge of the risks of infertility linked to these anti-cancer therapies, including new and future therapies, is essential to inform patients and offer them access to fertility preservation. The main objective of the ISIS project is to assess the risk of infertility after breast cancer in young women. In the longer term, the results could allow new recommendations on the preservation of fertility in patients.

REALIGIST
Gastrointestinal stromal tumors (GIST) are rare cancers (800 new patients per year in France) which begin in specific cells of the wall of the digestive tract, related to the large family of sarcomas. Despite the discovery of genetic abnormalities within these tumors and major therapeutic advances in the field, a large number of clinical and therapeutic questions remain unresolved. Supported by 7 CLCCs, the REALIGIST project will make it possible to create an unprecedented cohort of patients with GIST in France. By combining for the first time clinical and biological data from “real life” care and data from the SNDS, this project will make it possible to identify potential risk factors, analyze patient care pathways, and identify new factors associated with success or resistance to cancer treatment.

DASTO UNIBASE
The project focuses on predicting the risk of venous thromboembolic disease (VTE)1 in cancer patients, with the aim of understanding the risk factors within a cohort of 100,000 patients. The data from the SNDS will be correlated with that of the medical records analyzed by the ConSoRe tool. Involving 4 CLCCs, DASTO UNIBASE offers a unique approach that captures these risk factors throughout patient care, both in hospital and outpatient settings. This project is a data integration model aimed directly at improving patient care and the evolution of the care pathway.

(1) Disease of the veins which manifests as venous thrombosis (clot in a vein) or pulmonary embolism (clot in an artery of the lungs)


ABOUT UNICANCER
Unicancer is the only French hospital network 100% dedicated to the fight against cancer and the only national hospital federation dedicated to oncology. It brings together the 18 French Cancer Centers (CLCC), private non-profit health establishments, spread over 20 hospital sites in France, as well as the Avignon-Provence Cancer Institute (ICAP), as affiliated institution.
The CLCCs take care of nearly 530,000 patients per year (short-stay, HAD and outpatient procedures). Unicancer is also the leading academic promoter of clinical trials in oncology, on a European scale, with 90 active clinical trials promoted, nearly 7,700 patients included, 63,000 patients registered in the ESME database. Recognized as a leader in research in France, the Unicancer network enjoys a worldwide reputation with the production of a third of French publications of international scope in oncology (source: bibliometric study/ Thomson Reuters). In total, nearly 700 clinical trials (inclusion or follow-up) are promoted in 2020 by the Unicancer network, more than 14% of CLCC patients are included in clinical trials and more than half of PHRCs assigned to CLCCs.
Unicancer’s 18 CLCCs and R&D department are ISO 9001 certified.


ABOUT THE HEALTH DATA HUB
The Health Data Hub is a public interest group created by the Law of July 24, 2019 relating to the organization and transformation of the health system. It brings together 56 stakeholders, the vast majority from the public authorities (CNAM, CNRS, France Assos Santé, etc.) and implements the major strategic orientations relating to the National Health Data System set by the State and in particular the Ministry of Solidarity and Health. It is a service intended for the health ecosystem, the actors behind the collection of data, the promoters of projects of general interest and civil society. In this sense, it promotes health innovation and the accessibility of data and knowledge through, among other things, unifying events such as the organization of data challenges and calls for projects.

#data#health#cancerology#cancer#clinics#patient care#oncology


We would love to give thanks to the writer of this article for this incredible web content

Innovative oncology projects rewarded: Unicancer and the Health Data Hub unveil the 3 winners of the UNIBASE Call for Expression of Interest (AMI)


You can find our social media profiles , as well as other related pageshttps://www.ai-magazine.com/related-pages/